Table 1.
Inhibitory potency (EC50) and cytotoxicity (CC50) of compounds 5–25 and ribavirin (positive control) in HCV replicon assaya
| Compound | EC50b (μM) | CC50c (μM) | Antiviral indexd |
|---|---|---|---|
| 5 | 6.4 | 20.0 | 3.1 |
| 6 | 46.1 | >200 | 4.3 |
| 7 | 31.0 | >200 | >6.5 |
| 8 | 41.0 | 97.3 | 2.4 |
| 9 | 47.2 | 173 | 3.7 |
| 10 | 6.1 | 111 | 18.2 |
| 11 | 64.1 | >200 | >3.1 |
| 12 | 38.1 | 70.5 | 1.9 |
| 13 | 80.8 | >200 | >2.5 |
| 14 | 13.3 | 108 | 8.1 |
| 15 | 28.0 | 177 | 6.3 |
| 16 | 30.3 | >200 | >6.6 |
| 17 | 8.4 | 76.4 | 9.1 |
| 18 | >50 | 91.0 | <1.8 |
| 19 | 28.8 | 146 | 5.1 |
| 20 | 17.7 | 178 | 10.1 |
| 21 | 24.5 | 140 | 5.7 |
| 22 | >100 | — | — |
| 23 | 105 | >200 | >1.9 |
| 24 | 22.3 | >200 | >9.0 |
| 25 | >100 | — | — |
| Ribavirin | 54.8 | >200 | >3.7 |
a
The same experiment was performed at least three times independently.
b
Average of 50% effective concentrations.
c
Average of 50% cytotoxic concentrations.
d
Antiviral index was defined as the 50% toxic dose divided by the 50% effective dose.